The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study intends to evaluate the efficacy and safety of Dong Lingsheng Ji Granule in the
treatment of amyotrophic lateral sclerosis (spleen deficiency, kidney-yang deficiency
syndrome) in comparison with riluzole, so as to provide data support for marketing
application or subsequent clinical research design.